These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 20403731

  • 1. Effect of combining ACE inhibitor and statin in lupus-prone mice.
    Shimazu H, Kinoshita K, Hino S, Yano T, Kishimoto K, Nagare Y, Nozaki Y, Sugiyama M, Ikoma S, Funauchi M.
    Clin Immunol; 2010 Aug; 136(2):188-96. PubMed ID: 20403731
    [Abstract] [Full Text] [Related]

  • 2. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus.
    Cash H, Relle M, Menke J, Brochhausen C, Jones SA, Topley N, Galle PR, Schwarting A.
    J Rheumatol; 2010 Jan; 37(1):60-70. PubMed ID: 19955044
    [Abstract] [Full Text] [Related]

  • 3. Activated protein C attenuates systemic lupus erythematosus and lupus nephritis in MRL-Fas(lpr) mice.
    Lichtnekert J, Rupanagudi KV, Kulkarni OP, Darisipudi MN, Allam R, Anders HJ.
    J Immunol; 2011 Sep 15; 187(6):3413-21. PubMed ID: 21849682
    [Abstract] [Full Text] [Related]

  • 4. Chemokine receptor Ccr2 deficiency reduces renal disease and prolongs survival in MRL/lpr lupus-prone mice.
    Pérez de Lema G, Maier H, Franz TJ, Escribese M, Chilla S, Segerer S, Camarasa N, Schmid H, Banas B, Kalaydjiev S, Busch DH, Pfeffer K, Mampaso F, Schlöndorff D, Luckow B.
    J Am Soc Nephrol; 2005 Dec 15; 16(12):3592-601. PubMed ID: 16267157
    [Abstract] [Full Text] [Related]

  • 5. Clear suppression of Th1 responses but marginal amelioration of autoimmune manifestations by IL-12p40 transgene in MRL-FAS(lprcg)/FAS(lprcg) mice.
    Yasuda T, Yoshimoto T, Tsubura A, Matsuzawa A.
    Cell Immunol; 2001 Jun 15; 210(2):77-86. PubMed ID: 11520074
    [Abstract] [Full Text] [Related]

  • 6. Abrogation of skin disease in LUPUS-prone MRL/FASlpr mice by means of a novel tylophorine analog.
    Choi JY, Gao W, Odegard J, Shiah HS, Kashgarian M, McNiff JM, Baker DC, Cheng YC, Craft J.
    Arthritis Rheum; 2006 Oct 15; 54(10):3277-83. PubMed ID: 17009262
    [Abstract] [Full Text] [Related]

  • 7. Fc receptor-independent development of autoimmune glomerulonephritis in lupus-prone MRL/lpr mice.
    Matsumoto K, Watanabe N, Akikusa B, Kurasawa K, Matsumura R, Saito Y, Iwamoto I, Saito T.
    Arthritis Rheum; 2003 Feb 15; 48(2):486-94. PubMed ID: 12571859
    [Abstract] [Full Text] [Related]

  • 8. Implication of allelic polymorphism of osteopontin in the development of lupus nephritis in MRL/lpr mice.
    Miyazaki T, Ono M, Qu WM, Zhang MC, Mori S, Nakatsuru S, Nakamura Y, Sawasaki T, Endo Y, Nose M.
    Eur J Immunol; 2005 May 15; 35(5):1510-20. PubMed ID: 15832294
    [Abstract] [Full Text] [Related]

  • 9. Vaccination with autoreactive CD4(+)Th1 clones in lupus-prone MRL/Mp-Fas(lpr/lpr) mice.
    Fujii T, Okada M, Fujita Y, Sato T, Tanaka M, Usui T, Umehara H, Mimori T.
    J Autoimmun; 2009 Sep 15; 33(2):125-34. PubMed ID: 19596182
    [Abstract] [Full Text] [Related]

  • 10. CXCR3 mediates renal Th1 and Th17 immune response in murine lupus nephritis.
    Steinmetz OM, Turner JE, Paust HJ, Lindner M, Peters A, Heiss K, Velden J, Hopfer H, Fehr S, Krieger T, Meyer-Schwesinger C, Meyer TN, Helmchen U, Mittrücker HW, Stahl RA, Panzer U.
    J Immunol; 2009 Oct 01; 183(7):4693-704. PubMed ID: 19734217
    [Abstract] [Full Text] [Related]

  • 11. Anti-monocyte chemoattractant protein-1 gene therapy attenuates nephritis in MRL/lpr mice.
    Shimizu S, Nakashima H, Masutani K, Inoue Y, Miyake K, Akahoshi M, Tanaka Y, Egashira K, Hirakata H, Otsuka T, Harada M.
    Rheumatology (Oxford); 2004 Sep 01; 43(9):1121-8. PubMed ID: 15213333
    [Abstract] [Full Text] [Related]

  • 12. Activation of toll-like receptor-9 induces progression of renal disease in MRL-Fas(lpr) mice.
    Anders HJ, Vielhauer V, Eis V, Linde Y, Kretzler M, Perez de Lema G, Strutz F, Bauer S, Rutz M, Wagner H, Gröne HJ, Schlöndorff D.
    FASEB J; 2004 Mar 01; 18(3):534-6. PubMed ID: 14734643
    [Abstract] [Full Text] [Related]

  • 13. Amelioration of autoimmune nephritis by imatinib in MRL/lpr mice.
    Sadanaga A, Nakashima H, Masutani K, Miyake K, Shimizu S, Igawa T, Sugiyama N, Niiro H, Hirakata H, Harada M.
    Arthritis Rheum; 2005 Dec 01; 52(12):3987-96. PubMed ID: 16320345
    [Abstract] [Full Text] [Related]

  • 14. Soy isoflavones supplementation alleviates disease severity in autoimmune-prone MRL-lpr/lpr mice.
    Hong Y, Wang T, Huang C, Cheng W, Lin B.
    Lupus; 2008 Sep 01; 17(9):814-21. PubMed ID: 18755863
    [Abstract] [Full Text] [Related]

  • 15. Correlation of renal tubular epithelial cell-derived interleukin-18 up-regulation with disease activity in MRL-Faslpr mice with autoimmune lupus nephritis.
    Faust J, Menke J, Kriegsmann J, Kelley VR, Mayet WJ, Galle PR, Schwarting A.
    Arthritis Rheum; 2002 Nov 01; 46(11):3083-95. PubMed ID: 12428253
    [Abstract] [Full Text] [Related]

  • 16. Piperlongumine alleviates lupus nephritis in MRL-Fas(lpr) mice by regulating the frequency of Th17 and regulatory T cells.
    Yao L, Chen HP, Ma Q.
    Immunol Lett; 2014 Sep 01; 161(1):76-80. PubMed ID: 24837470
    [Abstract] [Full Text] [Related]

  • 17. Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus.
    Okazaki H, Hirata D, Kamimura T, Sato H, Iwamoto M, Yoshio T, Masuyama J, Fujimura A, Kobayashi E, Kano S, Minota S.
    J Rheumatol; 2002 Apr 01; 29(4):707-16. PubMed ID: 11950011
    [Abstract] [Full Text] [Related]

  • 18. Antagonist of monocyte chemoattractant protein 1 ameliorates the initiation and progression of lupus nephritis and renal vasculitis in MRL/lpr mice.
    Hasegawa H, Kohno M, Sasaki M, Inoue A, Ito MR, Terada M, Hieshima K, Maruyama H, Miyazaki J, Yoshie O, Nose M, Fujita S.
    Arthritis Rheum; 2003 Sep 01; 48(9):2555-66. PubMed ID: 13130475
    [Abstract] [Full Text] [Related]

  • 19. Interferon-beta: a therapeutic for autoimmune lupus in MRL-Faslpr mice.
    Schwarting A, Paul K, Tschirner S, Menke J, Hansen T, Brenner W, Kelley VR, Relle M, Galle PR.
    J Am Soc Nephrol; 2005 Nov 01; 16(11):3264-72. PubMed ID: 16221871
    [Abstract] [Full Text] [Related]

  • 20. Treatment with testosterone or estradiol in melatonin treated females and males MRL/MpJ-Faslpr mice induces negative effects in developing systemic lupus erythematosus.
    Jimenez-Caliani AJ, Jimenez-Jorge S, Molinero P, Rubio A, Guerrero JM, Osuna C.
    J Pineal Res; 2008 Sep 01; 45(2):204-11. PubMed ID: 18507713
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.